In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Orphan Therapeutics, LLC

http://www.orphantherapeutics.com/

Latest From Orphan Therapeutics, LLC

End Of US FDA’s Very Fast Reviews? 2022 Novel Approvals Stayed Close To PDUFA Timeframes

Moderation was a theme of the year in novel approvals, as CDER’s median review time rose for the first time in five years and even the center’s fastest approval took more than seven months. A Pink Sheet infographic breaks down which review pathways did the best last year. 

Pink Sheet Perspectives US FDA Performance Tracker

Tech Transfer Roundup: Tiba And CEPI Strategize Together On ‘Disease X’

Immix collaborates with Israeli research institutions on BCMA-targeted CAR-T therapy. NeoImmuneTech/NIAID alliance could pave way for “animal rule” approval in acute radiation syndrome.

Tech Transfer Round-Up Deals

Lockdown To Reopening: China Rebound Uncertain As Biotech Remains In Survival Mode

The short-notice reopening of the country made 2022 a tough year for the health sector in China, where divestments, cash crunches and commercial challenges abounded. Throughout the year, despite clinical trial activity continuing to blossom, multiple Chinese innovative drug developers faced setbacks in the US from regulatory rejections of oncology products. Meanwhile, others quietly scaled back their operations in China, hit by the negative impact of deep price cuts.

China Scrip Perspectives

China Stockpiles Antivirals, Scraps Quarantine To Further Reopen Borders

Incoming visitors won't be required to be centrally quarantined in designated facilities starting 8 January while the national health authority also calls to stockpile three months supply of antivirals to tackle acute shortages across the nation.

Coronavirus COVID-19 Policy
See All

Company Information

  • Industry
  • Pharmaceuticals
UsernamePublicRestriction

Register